Top-Quality SLU-PP-332 Powder For Bodybuilding CAS:303760-60-3

   What SLU-PP-332 Actually Is

    Let us start with a fundamental clarification: SLU-PP-332 is not a peptide. It is frequently misclassified as such in online discussions, but structurally and pharmacologically, it is a synthetic small-molecule ligand for nuclear transcription factors. Its molecular formula is C₁₈H₁₄N₂O₂, with a molecular weight of 290.32 g/mol. In its raw powder form, it typically appears as a white to off-white crystalline solid.

    The compound was developed at Saint Louis University by the Burris laboratory and first characterized in a 2023 publication in ACS Chemical Biology. It was designed as a pharmacological research tool to study the biology of estrogen-related receptors (ERRs)-a family of orphan nuclear receptors that play a central role in regulating cellular energy metabolism.

    Crucially, estrogen-related receptors are not estrogen receptors. Despite the similar name, ERRs do not bind estrogen. This distinction is critical because it addresses one of the most persistent and unfounded concerns surrounding this compound: that it might exert estrogenic effects or disrupt endogenous hormone balance. ERRα, ERRβ, and ERRγ are constitutively active transcription factors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid metabolism. SLU-PP-332 acts as a pan-agonist, activating all three subtypes simultaneously, with the highest potency for ERRα (EC₅₀ = 98 nM), followed by ERRβ (230 nM) and ERRγ (430 nM).

    The mechanism of SLU-PP-332 is elegant in its simplicity and profound in its implications for metabolic health and performance. When the compound binds to ERRα, it stabilizes the receptor's active conformation and enhances its interaction with coactivator proteins-most notably PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). PGC-1α is often described as the "master regulator" of mitochondrial biogenesis.

    This activation cascade produces several downstream effects:

    Mitochondrial Biogenesis: SLU-PP-332 upregulates the expression of TFAM (mitochondrial transcription factor A), leading to the creation of new mitochondria within skeletal muscle cells. More mitochondria mean greater aerobic capacity and enhanced energy production.

    Enhanced Fatty Acid Oxidation: The compound increases the expression of CPT1 (carnitine palmitoyltransferase 1) and MCAD (medium-chain acyl-CoA dehydrogenase), enzymes critical for the transport and β-oxidation of fatty acids. This shifts the body's metabolic preference toward fat as a primary fuel source.

    Improved Glucose Metabolism: SLU-PP-332 enhances the expression of GLUT4 glucose transporters in muscle tissue, improving insulin sensitivity and glucose uptake. In animal models, this has translated to a 40% improvement in glucose tolerance and a 25-30% decrease in fasting insulin levels.

    AMPK Stimulation: The compound activates AMPK (AMP-activated protein kinase) signaling, mimicking an energy-deprived cellular state that further promotes fat oxidation and metabolic efficiency.

    In practical terms, SLU-PP-332 tricks the body into acting as though it has already performed aerobic exercise, triggering the same genetic programs normally activated by endurance training.

    Not all SLU-PP-332 powder is created equal. Given that this compound exists in a regulatory gray area-it is not FDA-approved for human use and is sold exclusively as a research chemical-quality control is entirely dependent on the supplier. Top-quality material should exhibit the following characteristics:

    Purity: High-quality SLU-PP-332 powder should be ≥98% pure. Impurities can not only reduce efficacy but also introduce unknown safety risks.

    Appearance: The powder should be white to off-white in color. Any discoloration, clumping, or unusual odor may indicate degradation or contamination.

    Solubility: SLU-PP-332 is soluble in DMSO (up to 75 mg/mL) and ethanol but is insoluble in water. This has significant implications for administration, as discussed below.

    Storage: The compound should be stored in a cool, dry place, protected from light. For long-term storage, keeping it at -20°C can preserve stability for up to three years.

    Third-Party Testing: Reputable suppliers should provide certificates of analysis (COAs) from independent laboratories verifying purity and identity. Given the absence of regulatory oversight, this is arguably the most important quality indicator.

    For the physique athlete, SLU-PP-332 offers a unique set of applications that differentiate it from traditional anabolic agents or fat burners.

    Fat Loss Without Muscle Wasting

    One of the most significant challenges during a cutting phase is preserving lean muscle mass while in a caloric deficit. Traditional fat loss compounds often achieve their effects through appetite suppression or increased thermogenesis, but they do not necessarily protect muscle tissue. SLU-PP-332 takes a fundamentally different approach. By promoting fatty acid oxidation and improving metabolic efficiency, it facilitates fat loss while simultaneously supporting muscle function. In animal studies, obese mice administered SLU-PP-332 experienced an 18-24% reduction in body weight and a 30-35% decrease in white adipose tissue mass. Importantly, these effects occurred without reducing food intake, meaning the compound increases energy expenditure rather than suppressing appetite.

    Enhanced Endurance and Work Capacity

    Endurance is a limiting factor in many bodybuilding protocols, particularly during high-volume training phases or when incorporating cardiovascular conditioning. SLU-PP-332 has demonstrated remarkable endurance-enhancing effects in preclinical models. In one study, normal-weight mice administered the compound were able to run for 70% longer and 45% further than untreated mice. This translates to improved training capacity, allowing for more productive sessions and better recovery between sets.

    Metabolic Health and Nutrient Partitioning

    Beyond the immediate performance benefits, SLU-PP-332 may offer metabolic health advantages that support long-term bodybuilding goals. It has been shown to improve insulin sensitivity, reduce liver fat accumulation, and lower triglyceride levels. For bodybuilders who frequently cycle between bulking and cutting phases-often involving significant fluctuations in caloric intake and macronutrient composition-maintaining metabolic flexibility is crucial.

    A Note on What It Does NOT Do

    It is equally important to understand what SLU-PP-332 does not do. It is not an anabolic agent. It does not directly stimulate muscle protein synthesis or promote hypertrophy in the way that androgens or selective androgen receptor modulators (SARMs) do. Its value lies in metabolic enhancement, endurance improvement, and fat loss support-not in building muscle mass directly. This distinction is frequently lost in the hype surrounding the compound.

    Because SLU-PP-332 has not been approved for human use, there is no official dosage guideline. The information available comes from preclinical animal studies and anecdotal reports from individuals who have chosen to experiment with the compound.

    Preclinical Reference: In rodent studies, typical doses ranged from 3 to 50 mg/kg administered twice daily. When scaled to human-equivalent doses using standard allometric calculations, this translates to a theoretical range of approximately 200-600 mg per day for a 70 kg individual. However, this is a research estimate derived from animal models, not a validated human dose, and human response may differ significantly.

    Anecdotal Bodybuilding Protocols: Based on user reports across various forums, the practical dosage range for bodybuilders appears to be considerably lower than the theoretical human-equivalent dose. Many users report starting at 250-500 mcg (micrograms) per day, typically divided into two or three doses throughout the day. Some individuals have experimented with higher doses, up to 1 mg three times daily (3 mg total per day), though results appear to be highly individual.

    Titration Strategy: Given the wide variability in individual response, a prudent approach involves starting low and titrating upward gradually. Beginning at 250-300 mcg per day for the first week allows the user to assess tolerance and initial effects. If well-tolerated, the dose can be increased incrementally-for example, by 250 mcg per week-until the desired effects are observed or side effects become noticeable. Some users report that effects become perceptible at doses as low as 500 mcg per day, while others require higher amounts to achieve noticeable results.

    Timing: Due to its estimated 8-10 hour half-life in rodents, dividing the daily dose into two or three administrations helps maintain more consistent plasma levels. For individuals who experience sleep disruption, taking the final dose early in the day is advisable.

    The optimal cycle length for SLU-PP-332 remains a matter of debate, given the absence of clinical data. However, emerging consensus from the bodybuilding community suggests several approaches:

    Standard Cycle (4-8 Weeks): Most users report running SLU-PP-332 for 4 to 8 weeks, which aligns with typical research study durations. This timeframe appears sufficient to observe meaningful effects while minimizing the risk of diminishing returns or potential tolerance development.

    Extended Cycle (3-4 Months): Some users advocate for longer cycles of 3 to 4 months, followed by a 1-month washout period. This approach is based on the premise that mitochondrial biogenesis is a gradual process that may require extended stimulation to produce significant adaptations.

    The "Tune-Up" Phase: One proposed strategy involves running SLU-PP-332 solo for 4-6 weeks as a "tune-up" phase, during which the user titrates the dose to find their individual sweet spot. This allows for a controlled assessment of the compound's effects before potentially stacking it with other agents.

    Stacking Considerations: SLU-PP-332 is frequently discussed in the context of stacking with other compounds. Some users combine it with MOTS-C, another mitochondrial-enhancing peptide, on the theory that they operate through complementary pathways. Others stack it with GLP-1 agonists like retatrutide for enhanced fat loss effects, though SLU-PP-332 does not play a significant role in appetite suppression. The combination of SLU-PP-332 with BAM15-another mitochondrial uncoupler-has been the subject of debate, with some experts warning that combining multiple mitochondrial modulators could potentially be counterproductive or increase the risk of oxidative stress.

    The pharmacokinetic profile of SLU-PP-332 is not fully characterized, and publicly available data remains limited. What is known comes primarily from preclinical studies in rodent models.

    Half-Life: The estimated plasma half-life in rodents is approximately 8-10 hours. This suggests that the compound is cleared relatively quickly from the system, necessitating multiple daily administrations to maintain therapeutic levels.

    Duration of Action: Based on observed pharmacological effects, the duration of action is estimated to be between 12 and 18 hours. This aligns with the recommendation to divide the daily dose into two or three administrations.

    Absorption and Distribution: Oral bioavailability has not been definitively established. In preclinical studies, SLU-PP-332 has been administered via intraperitoneal injection. The compound is widely distributed to metabolically active tissues, including the liver, skeletal muscle, and adipose tissue, with high mitochondrial tropism. Blood-brain barrier penetration is limited, estimated at less than 5% of plasma levels.

    Metabolism and Elimination: The compound is primarily metabolized by hepatic CYP450 enzymes, with phase II glucuronidation as a secondary pathway. Elimination is predominantly via biliary and fecal routes.

    Key Caveat: These parameters are derived from rodent studies and may not be directly translatable to humans. The absence of human pharmacokinetic data is a significant limitation in understanding how the compound behaves in the target population.

    One of the most frequently asked questions about SLU-PP-332 concerns post-cycle therapy (PCT). The answer is more straightforward than with traditional anabolic agents, but it still requires careful consideration.

    No Hormonal Suppression: SLU-PP-332 is non-hormonal and does not suppress endogenous production of any key hormone or peptide. Unlike androgens or SARMs, it does not act on the hypothalamic-pituitary-gonadal axis. Therefore, traditional PCT protocols-such as those involving SERMs (tamoxifen, clomiphene) or aromatase inhibitors-are not required or appropriate.

    What PCT Means for SLU-PP-332: In the context of this compound, "PCT" refers not to hormonal restoration but to a structured washout or recovery period. This serves several purposes:

    Assessing Baseline: A washout period allows the user to evaluate whether the benefits observed during the cycle persist or are dependent on continued compound administration.

    Preventing Tolerance: While tolerance to SLU-PP-332 has not been formally studied, cycling off periodically is a prudent measure to prevent potential receptor desensitization or diminishing returns.

    Monitoring Recovery: The washout period provides an opportunity to monitor any changes in biomarkers-such as fasting glucose, insulin sensitivity, or lipid panels-and ensure that no adverse effects have emerged.

    Suggested PCT Protocol: A washout period of 4 weeks following a cycle of 8-12 weeks is commonly recommended. During this time, the user should continue to monitor training performance, body composition, and subjective well-being. Supplementation with antioxidants-such as CoQ10, vitamin C, or C60-may be considered to support cellular health and mitigate any potential oxidative stress.

    Monitoring: Given the experimental nature of this compound, regular monitoring of relevant biomarkers is strongly advised. This includes fasting glucose, insulin, lipid panel (cholesterol, triglycerides), and liver function tests (AST, ALT). Heart rate variability (HRV) and resting heart rate can also provide useful insights into autonomic nervous system function and recovery status.

Trade names	SLU-PP-332,4-Hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide
CAS	303760-60-3
Molar mass	290.322
MF	C18H14N2O2
Purity	Above 98%
Apprarance	White Crystalline Powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                  

 

    SLU-PP-332 represents a genuinely novel approach to metabolic enhancement and performance support. Its mechanism-activating the body's own exercise-response pathways at the genetic level-is fundamentally different from traditional performance-enhancing drugs. For the bodybuilder, it offers the potential to enhance fat loss, improve endurance, and support metabolic health without the hormonal side effects associated with androgenic compounds.

Hot Tags: top-quality slu-pp-332 powder for bodybuilding cas:303760-60-3, China top-quality slu-pp-332 powder for bodybuilding cas:303760-60-3 manufacturers, suppliers, factory, Anabolic androgenic steroid Trenbolone Acetate, Clomid Treatment of female anovulatory infertility, Clostebol Acetate, Nolvadex to treat or prevent breast cancer, Testosterone, Trenbolone Enanthate